QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
Log in
NYSEAMERICAN:LCTX

Lineage Cell Therapeutics Stock Forecast, Price & News

$1.35
+0.05 (+3.85 %)
(As of 10/19/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.27
Now: $1.35
$1.37
50-Day Range N/A
52-Week Range
$0.53
Now: $1.35
$1.67
Volume909,815 shs
Average Volume984,103 shs
Market Capitalization$202.47 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:LCTX
CUSIPN/A
CIKN/A
Phone510-871-4188
Employees50

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$202.47 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$1.35
+0.05 (+3.85 %)
(As of 10/19/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LCTX News and Ratings via Email

Sign-up to receive the latest news and ratings for LCTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Lineage Cell Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lineage Cell Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Lineage Cell Therapeutics
.

When is Lineage Cell Therapeutics' next earnings date?

Lineage Cell Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Lineage Cell Therapeutics
.

How were Lineage Cell Therapeutics' earnings last quarter?

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) posted its earnings results on Thursday, August, 6th. The company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). The company had revenue of $0.39 million for the quarter, compared to analyst estimates of $0.76 million.
View Lineage Cell Therapeutics' earnings history
.

What price target have analysts set for LCTX?

5 equities research analysts have issued 12 month price objectives for Lineage Cell Therapeutics' shares. Their forecasts range from $3.00 to $6.00. On average, they anticipate Lineage Cell Therapeutics' share price to reach $4.33 in the next year. This suggests a possible upside of 221.0% from the stock's current price.
View analysts' price targets for Lineage Cell Therapeutics
.

Are investors shorting Lineage Cell Therapeutics?

Lineage Cell Therapeutics saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 7,260,000 shares, an increase of 28.0% from the September 15th total of 5,670,000 shares. Based on an average daily volume of 713,400 shares, the short-interest ratio is currently 10.2 days. Currently, 4.9% of the shares of the company are sold short.
View Lineage Cell Therapeutics' Short Interest
.

Who are some of Lineage Cell Therapeutics' key competitors?

What other stocks do shareholders of Lineage Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lineage Cell Therapeutics investors own include Matinas BioPharma (MTNB), BioNano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI), Cannabics Pharmaceuticals (CNBX), Enerplus (ERF), KushCo (KSHB) and Zosano Pharma (ZSAN).

Who are Lineage Cell Therapeutics' key executives?

Lineage Cell Therapeutics' management team includes the following people:
  • Mr. Brian M. Culley, CEO, Pres & Director (Age 49, Pay $772.74k)
  • Ms. Brandi L. Roberts, Chief Financial Officer (Age 46, Pay $550.01k)
  • Mr. Chase C. Leavitt, Gen. Counsel & Corp. Sec. (Age 39, Pay $321.79k)
  • Ioana C. Hone, Director of Investor Relations
  • Mr. James Knight, Sr. VP & Head of Corp. Devel.

What is Lineage Cell Therapeutics' stock symbol?

Lineage Cell Therapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "LCTX."

How do I buy shares of Lineage Cell Therapeutics?

Shares of LCTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Lineage Cell Therapeutics' stock price today?

One share of LCTX stock can currently be purchased for approximately $1.35.

How big of a company is Lineage Cell Therapeutics?

Lineage Cell Therapeutics has a market capitalization of $202.47 million. Lineage Cell Therapeutics employs 50 workers across the globe.

What is Lineage Cell Therapeutics' official website?

The official website for Lineage Cell Therapeutics is www.lineagecell.com.

How can I contact Lineage Cell Therapeutics?

The company can be reached via phone at 510-871-4188.

This page was last updated on 10/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.